Inmune Bio Inc Stock Price, News & Analysis

INmune Bio Inc. (NASDAQ: INMB) has published a landmark paper in the Journal for ImmunoTherapy of Cancer, detailing the biology of their Natural Killer cancer immunotherapy, INKmune™. The study demonstrates that memory-like natural killer (mlNK) cells, generated by either cytokine or INKmune™ priming, show increased cytotoxicity against multiple tumor types. Notably, mlNK cells from cancer patients are as potent as those from healthy volunteers, supporting INKmune's in vivo treatment approach.

The research provides insights into NK cell memory mechanisms, potentially leading to innovative treatments for hematological malignancies and solid tumors. INKmune™ priming increases proteins that protect NK cells in the tumor microenvironment, which is promising for their ongoing clinical trial in metastatic castration-resistant prostate cancer. The study also demonstrates in vivo generation of mlNK cells and their enhanced metabolic function, suggesting improved performance in the tumor microenvironment.

INmune Bio (NASDAQ: INMB) has completed a blinded interim analysis of its Phase II Alzheimer’s Disease (AD) trial, AD02. The trial uses the Early Mild Alzheimer’s Cognitive Composite (EMACC) as its primary endpoint. The analysis, conducted by third-party statisticians and neuropsychologists, confirmed the trial’s design, operational execution, and data management are of high quality. The interim results showed no need to change the trial design or sample size, reinforcing the EMACC's suitability in measuring cognitive changes in early AD. EMACC was chosen for its objective and validated cognitive measures, previously demonstrated in Biogen studies, and its strong association with biological markers of inflammation. Dr. CJ Barnum, VP of Neuroscience, endorsed the positive findings, along with consultants Dr. Paul Maruff and Dr. Judith Jaeger, citing the EMACC’s high acceptability and reliability in detecting cognitive changes in patients with early AD.

INmune Bio (NASDAQ: INMB), a clinical-stage inflammation and immunology company, will join the Russell 3000® Index following the 2024 Russell US Indexes annual reconstitution. Effective July 1, the inclusion is based on market capitalization rankings as of April 30. This membership also means automatic inclusion in either the Russell 1000® or Russell 2000® Index, and relevant growth and value style indexes, lasting one year. CEO Dr. Raymond J. Tesi believes this will boost the company's visibility and attract more investors. The Russell indexes, used by investment managers for benchmark strategies, reflect $10.5 trillion in assets.

INmune Bio Inc. announced its first-quarter 2024 financial results and provided a business update, highlighting milestones in their DN-TNF, INB03 cancer, and INKmune platforms. The company raised $14.5 million in equity capital, completed the first dosing in a Phase I/II trial of INKmune for mCRPC, and disclosed a net loss of $11.0 million for the quarter ended March 31, 2024.

INmune Bio Inc. will report its first quarter 2024 financial results and provide a corporate update on May 9. The clinical-stage immunology company is focused on developing treatments leveraging a patient's innate immune system to combat diseases. A conference call and webcast will be hosted at 4:30 PM ET on the same day.

INmune Bio Inc. provides an update on two patients from the Phase 1b Alzheimer’s Disease Trial who have been receiving XPro™ for over three years under the Australian compassionate use program. Both patients have shown stable cognitive function and a desire to continue treatment. The long-term administration of XPro™ has been safe and well-tolerated, according to primary care physicians.

INmune Bio Inc., a clinical-stage immunology company, has completed the first cohort and initiated the second cohort of a Phase 1/2 study of INKmune™ Natural Killer Cell Therapy for metastatic castration-resistant prostate cancer. The company is encouraged by the safety and efficacy of the therapy, with approval granted to proceed with the second dose level. Prof. Mark Lowdell Ph.D., CSO of INmune Bio, highlights the potential of INKmune to transform resting NK cells into cancer-killing cells, offering a promising therapy for prostate cancer patients.